Newcells Biotech builds in vitro models and services to de-risk and improve clinical translation and drug discovery
Based in Newcastle upon Tyne, UK
Founded in 2015 as a spin-out from Newcastle University
Worldwide collaborations with pharmas, biotechs & academic centres of excellence
State-of-the-art facilities in the heart of a science campus
Dr Mike Nicholds, CEO, talks about the drive behind the company and the mission to improve clinical translation
Newcells Biotech provides clients with validated in vitro tools to understand how drugs interact with tissues. We enable the generation of robust and informative data to support critical decisions during any stage of drug-development.
What drives us At Newcells Biotech, we believe that improving the in vitro models available for drug discovery and development scientists is a key method for increasing the efficiency of in-vitro to in-vivo translation. An organoid model is created through organoid culture, the process whereby 3D organoids are made from stem cells which can improve drug discovery and enhance treatment options through the study of human organoids. We offer several predictive models to be used in our services or to be purchased as a product. At Newcells Biotech, we apply our expertise of induced pluripotent stem cells (iPSCs), primary tissues, cellular physiology and organoid technology to support our build of validated organoid models and assays that have proven to be predictive of how different drugs interact with tissues and organs. Through expert organoid research and studies, our proven organoid model is used across the UK in drug discovery trials in human organoids and for treatment in patients.
View our in vitro tissue models for drug discoveryFounders
Executive team
Scientific leadership
Non-executive board members
Non-Executive Director
Non-Executive Director
Non-Executive Director
Our services and products help our clients get the data they need
Combining expert know-how and extensive capabilities, our organoid model services and & products in the UK generate predictive human in vitro data. Our approach at Newcells Biotech is based on validated models which enables a deeper understanding of how new drugs interact with specific tissues and provide key mechanistic insights relating to the safety and efficacy of new therapeutic compounds of organoid model.
An organoid model produced in our facility is derived from stem cells and is developed using organoid culture combined with our in-depth expertise which supports study, design and execution. These 3D organoids, or organoid models, are:
- Characterised and tested to mimic the phenotype of the in vivo tissue
- Validated assays conducted under quality control to give data confidence
- Offered in both human and animal cell versions enables cross-species comparison
- Proven to provide predictive data on behaviour in vivo
- Adapted to medium throughput high content screening
- Proven in hundreds of customer studies on efficacy, safety and drug transport
Newcells Biotech’s models produce data you can rely on.
We are the leading provider of in vitro tissue models of the kidney, retina and lung in the UK.
Contact us
Our Investors
Newcells is funded by the founders, venture and private equity investors
